Intranasal administration of molecular-gated mesoporous nanoparticles to increase ponatinib delivery to the brain
Background: Glioblastoma is the most common and lethal brain cancer. New treatments are needed. However, the presence of the blood-brain barrier is limiting the development of new treatments directed toward the brain, as it restricts the access and distribution of drugs to the CNS. Materials & methods: In this work, two different nanoparticles (i.e., mesoporous silica nanoparticles and magnetic mesoporous silica nanoparticles) loaded with ponatinib were prepared. Results & conclusion: Both particles were characterized and tested in vitro and in vivo, proving that they are not toxic for blood-brain barrier cells and they increase the amount of drug reaching the brain when administered intranasally in comparison with the results obtained for the free drug.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Nanomedicine (London, England) - 18(2023), 25 vom: 21. Okt., Seite 1799-1813 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sánchez-Dengra, Bárbara [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4340891KFS |
|---|
| Anmerkungen: |
Date Completed 01.12.2023 Date Revised 22.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/nnm-2023-0131 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364822767 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364822767 | ||
| 003 | DE-627 | ||
| 005 | 20240423232028.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/nnm-2023-0131 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1384.xml |
| 035 | |a (DE-627)NLM364822767 | ||
| 035 | |a (NLM)37990994 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sánchez-Dengra, Bárbara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intranasal administration of molecular-gated mesoporous nanoparticles to increase ponatinib delivery to the brain |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2023 | ||
| 500 | |a Date Revised 22.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Glioblastoma is the most common and lethal brain cancer. New treatments are needed. However, the presence of the blood-brain barrier is limiting the development of new treatments directed toward the brain, as it restricts the access and distribution of drugs to the CNS. Materials & methods: In this work, two different nanoparticles (i.e., mesoporous silica nanoparticles and magnetic mesoporous silica nanoparticles) loaded with ponatinib were prepared. Results & conclusion: Both particles were characterized and tested in vitro and in vivo, proving that they are not toxic for blood-brain barrier cells and they increase the amount of drug reaching the brain when administered intranasally in comparison with the results obtained for the free drug | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a blood–brain barrier | |
| 650 | 4 | |a glioblastoma | |
| 650 | 4 | |a mesoporous nanoparticles | |
| 650 | 4 | |a ponatinib | |
| 650 | 4 | |a targeted drug delivery | |
| 650 | 7 | |a ponatinib |2 NLM | |
| 650 | 7 | |a 4340891KFS |2 NLM | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Silicon Dioxide |2 NLM | |
| 650 | 7 | |a 7631-86-9 |2 NLM | |
| 700 | 1 | |a Alfonso, María |e verfasserin |4 aut | |
| 700 | 1 | |a González-Álvarez, Isabel |e verfasserin |4 aut | |
| 700 | 1 | |a Bermejo, Marival |e verfasserin |4 aut | |
| 700 | 1 | |a González-Álvarez, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-Máñez, Ramón |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nanomedicine (London, England) |d 2006 |g 18(2023), 25 vom: 21. Okt., Seite 1799-1813 |w (DE-627)NLM17228452X |x 1748-6963 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2023 |g number:25 |g day:21 |g month:10 |g pages:1799-1813 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/nnm-2023-0131 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2023 |e 25 |b 21 |c 10 |h 1799-1813 | ||